ALK and lung adenocarcinoma: Zhou et al[6] first reported that a lung adenocarcinoma patient with an EGFR-mutant and an ALK fusion acquired resistance to osimertinib, but was sensitive to the combined treatment of gefitinib plus crizotinib.